Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

Compartmentalized microfluidic culture platform to study mechanism of paclitaxel-induced axonal degeneration

(2009) In Hong Yang et al.   EXPERIMENTAL NEUROLOGY

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

(2009) David R. Gandara et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer

(2008) Henrik Gréen et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Peripheral nerve damage associated with administration of taxanes in patients with cancer

(2008) Andreas A. Argyriou et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3

(2008) Chunshan Gui et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease

(2008) Helen E. Smith et al.   Pharmacogenetics and Genomics

Impact of genetic polymorphisms inCYP2C8and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids

(2008) Julia Kirchheiner et al.   PHARMACOGENOMICS